Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,501
  • Shares Outstanding, K 67,720
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,850 K
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36
Trade APTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.98
  • Most Recent Earnings $-0.31 on 05/18/23
  • Latest Earnings Date 01/02/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +78.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0090 +966.67%
on 12/19/23
0.0960 unch
on 12/29/23
+0.0325 (+51.18%)
since 11/29/23
3-Month
0.0090 +966.67%
on 12/19/23
0.0960 unch
on 12/29/23
+0.0286 (+42.43%)
since 09/29/23
52-Week
0.0090 +966.67%
on 12/19/23
0.7200 -86.67%
on 02/13/23
-0.2041 (-68.01%)
since 12/29/22

Most Recent Stories

More News
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus....

BMY : 48.67 (+0.77%)
ADMA : 6.15 (-0.81%)
EDIT : 5.44 (-1.98%)
APTX : 0.0960 (+3.11%)
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

MCK : 521.92 (+0.60%)
PKI : 115.24 (-0.91%)
APTX : 0.0960 (+3.11%)
BRBR : 53.73 (-0.92%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 891.95 (-0.23%)
RARE : 42.39 (-2.28%)
APTX : 0.0960 (+3.11%)
ETNB : 8.90 (+0.23%)
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

RHHBY : 30.3400 (+0.97%)
ADMA : 6.15 (-0.81%)
BPMC : 87.38 (-1.71%)
APTX : 0.0960 (+3.11%)
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

DVA : 128.10 (+1.58%)
APTX : 0.0960 (+3.11%)
BRBR : 53.73 (-0.92%)
SRZN : 9.33 (-0.32%)
Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up

Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.

SNY : 46.39 (+2.20%)
NVO : 123.35 (+0.49%)
ADMA : 6.15 (-0.81%)
APTX : 0.0960 (+3.11%)
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

PFE : 25.84 (+1.77%)
ADMA : 6.15 (-0.81%)
DCPH : 14.37 (+0.98%)
APTX : 0.0960 (+3.11%)
Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

AMGN : 267.66 (+1.87%)
HZNP : 116.30 (+0.04%)
ADMA : 6.15 (-0.81%)
APTX : 0.0960 (+3.11%)
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

ITCI : 73.64 (+2.28%)
ACAD : 16.95 (-0.70%)
AXSM : 67.89 (+3.30%)
APTX : 0.0960 (+3.11%)
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

GSK : 39.64 (+0.94%)
ACAD : 16.95 (-0.70%)
APTX : 0.0960 (+3.11%)
BLU : 14.74 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.1040
2nd Resistance Point 0.1000
1st Resistance Point 0.0980
Last Price 0.0960
1st Support Level 0.0920
2nd Support Level 0.0880
3rd Support Level 0.0860

See More

52-Week High 0.7200
Fibonacci 61.8% 0.4484
Fibonacci 50% 0.3645
Fibonacci 38.2% 0.2806
Last Price 0.0960
52-Week Low 0.0090

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar